Jean-Christophe Buge

USPTO Granted Patents = 11 (Patent Applications = 5)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 10 (Patent Applications = 14)

Average Co-Inventor Count = 2.2

ph-index = 2

Forward Citations = 24(Granted Patents)

Company Filing History:

8 out of 222

Galderma Research & Development

Galderma Laboratories Inc.

patents

Years Active: 2011-2022

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11234931 - No-rinse chemical foam containing brimonidine, and use thereof in the treatment of rosacea (2022-02-01),

2. 11160812 - No-rinse chemical foam containing clobetasol propionate, and use thereof in the treatment of psoriasis (2021-11-02),

3. 11020348 - No-rinse chemical foam containing trifarotene, and use thereof in the treatment of ichthyosis (2021-06-01),

4. 11020347 - No-rinse chemical foam containing trifarotene, and use thereof in the treatment of acne (2021-06-01),

5. 10987307 - No-rinse chemical foam comprising ivermectin (2021-04-27),

6. 10821076 - Self-foaming cleansing composition containing clobetasol propionate, and use thereof in the treatment of psoriasis (2020-11-03),

7. 10813860 - Leave-in chemical foam comprising benzoyl peroxide (2020-10-27),

8. 10449175 - Rinse-off chemical mousse containing benzoyl peroxide (2019-10-22),

9. 10201517 - Brimonidine gel compositions and methods of use (2019-02-12),

10. 8163725 - Gel compositions and methods of use (2012-04-24),

11. 8053427 - Brimonidine gel composition (2011-11-08),

Title: Innovations by Jean-Christophe Buge

Introduction

Jean-Christophe Buge is a notable inventor based in Nice, France. He has made significant contributions to the field of dermatological treatments, holding a total of 11 patents. His work primarily focuses on innovative topical applications for skin conditions.

Latest Patents

Among his latest patents, Jean-Christophe Buge has developed a no-rinse chemical foam containing brimonidine, which is used in the treatment of rosacea. This self-foaming composition includes brimonidine and is designed for no-rinse topical application. The formulation consists of at least one intermediate composition B that includes a gas-generating agent, and at least one intermediate composition A that activates this agent. Brimonidine or its pharmaceutically acceptable salts are present in one of these intermediate compositions. Additionally, he has patented a no-rinse chemical foam containing clobetasol propionate for the treatment of psoriasis. Similar to his other invention, this self-foaming composition is intended for topical application and includes a gas-generating agent and an activating agent.

Career Highlights

Jean-Christophe Buge has worked with prominent companies in the pharmaceutical industry, including Galderma Research & Development and Galderma R&D SNC. His experience in these organizations has allowed him to develop innovative solutions for skin care.

Collaborations

Throughout his career, Jean-Christophe has collaborated with various professionals, including Karine Nadau-Fourcade and Cyril Meunier. These collaborations have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Jean-Christophe Buge's contributions to dermatological innovations highlight his expertise and commitment to improving skin treatment options. His patents reflect a dedication to developing effective solutions for common skin conditions.

This text is generated by artificial intelligence and may not be accurate.